pCRP-mCRP Dissociation Mechanisms as Potential Targets for the Development of Small-Molecule Anti-Inflammatory Chemotherapeutics

Circulating C-reactive protein (CRP) is a key acute-phase protein and one of the main clinical biomarkers for inflammation and infection. CRP is an important upstream mediator of inflammation and is associated with the onset of a number of important disease states including cardiovascular disease and neurodegenerative disorders such as Alzheimer’s disease. This pentraxin exerts pro-inflammatory properties via dissociation of the pentamer (pCRP) to a monomeric form (mCRP). This dissociation is induced by binding of pCRP to cell surface phosphocholine residues exposed by the action of phospholipase A2 (PLA2). Given the association of CRP with the onset of a range of serious disease states this CRP dissociation process is a tempting drug target for the development of novel small-molecule therapeutics. This review will discuss potential targets for chemotherapeutic intervention elucidated during studies of CRP-mediated inflammation and provide an up-to-date summary of the development of small molecules, not only targeted directly at inhibiting conversion of pCRP to mCRP, but also those developed for activity against PLA2, given the key role of this enzyme in the activation of CRP.

[1]  Varnavas D. Mouchlis,et al.  2-Oxoesters: A Novel Class of Potent and Selective Inhibitors of Cytosolic Group IVA Phospholipase A2 , 2017, Scientific Reports.

[2]  Jie Yang,et al.  High-affinity recognition of the human C-reactive protein independent of phosphocholine. , 2017, Organic & biomolecular chemistry.

[3]  P. Meikle,et al.  Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites , 2017, Nature Communications.

[4]  N. Selmi,et al.  Discovery of AZD2716: A Novel Secreted Phospholipase A2 (sPLA2) Inhibitor for the Treatment of Coronary Artery Disease , 2016, ACS medicinal chemistry letters.

[5]  E. Stone,et al.  Monomeric C‐reactive protein and inflammation in age‐related macular degeneration , 2016, The Journal of pathology.

[6]  Qifeng Bai,et al.  An Intrinsically Disordered Motif Mediates Diverse Actions of Monomeric C-reactive Protein* , 2016, The Journal of Biological Chemistry.

[7]  T. Sawamura,et al.  Interplay between CRP, Atherogenic LDL, and LOX-1 and Its Potential Role in the Pathogenesis of Atherosclerosis. , 2016, Clinical chemistry.

[8]  J. Filep,et al.  C-reactive protein and inflammation: conformational changes affect function , 2015, Biological chemistry.

[9]  Yechun Xu,et al.  Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors. , 2015, Journal of medicinal chemistry.

[10]  G. Vilahur,et al.  Biological actions of pentraxins. , 2015, Vascular pharmacology.

[11]  S. Love,et al.  Monomeric C-reactive protein-a key molecule driving development of Alzheimer’s disease associated with brain ischaemia? , 2015, Scientific Reports.

[12]  A. A. Farooqui,et al.  Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders. , 2015, ACS chemical neuroscience.

[13]  Xin Wu,et al.  Increased monomeric CRP levels in acute myocardial infarction: a possible new and specific biomarker for diagnosis and severity assessment of disease. , 2015, Atherosclerosis.

[14]  Tomas Åkerud,et al.  Discovery of a novel pyrazole series of group X secreted phospholipase A2 inhibitor (sPLA2X) via fragment based virtual screening. , 2014, Bioorganic & medicinal chemistry letters.

[15]  E. Dennis,et al.  Inhibition of group IVA cytosolic phospholipase A2 by thiazolyl ketones in vitro, ex vivo, and in vivo. , 2014, Journal of medicinal chemistry.

[16]  B. Cummings,et al.  Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease. , 2014, Biochemical pharmacology.

[17]  Asher Mullard.  GSK's darapladib failures dim hopes for anti-inflammatory heart drugs , 2014, Nature Reviews Drug Discovery.

[18]  R. Virmani,et al.  Dissociation of Pentameric to Monomeric C-Reactive Protein Localizes and Aggravates Inflammation: In Vivo Proof of a Powerful Proinflammatory Mechanism and a New Anti-Inflammatory Strategy , 2014, Circulation.

[19]  P. Pais,et al.  Darapladib for preventing ischemic events in stable coronary heart disease. , 2014, The New England journal of medicine.

[20]  Y. Takada,et al.  The Binding of Monomeric C-Reactive Protein (mCRP) to Integrins αvβ3 and α4β1 Is Related to Its Pro-Inflammatory Action , 2014, PloS one.

[21]  N. Hübner,et al.  Rosuvastatin can block pro-inflammatory actions of transgenic human C-reactive protein without reducing its circulating levels. , 2014, Cardiovascular therapeutics.

[22]  J. Kastelein,et al.  Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. , 2014, JAMA.

[23]  Wei Zhang,et al.  Triazole derivatives: a series of Darapladib analogues as orally active Lp-PLA2 inhibitors. , 2013, Bioorganic & medicinal chemistry letters.

[24]  Y. Hu,et al.  Amides of 4-hydroxy-8-methanesulfonylamino-quinoline-2-carboxylic acid as zinc-dependent inhibitors of Lp-PLA₂. , 2013, Bioorganic & medicinal chemistry letters.

[25]  Wei Zhang,et al.  Design and synthesis of imidazole and triazole derivatives as Lp-PLA₂ inhibitors and the unexpected discovery of highly potent quaternary ammonium salts. , 2013, Bioorganic & medicinal chemistry letters.

[26]  Steven J Brown,et al.  Selective inhibitors and tailored activity probes for lipoprotein-associated phospholipase A(2). , 2013, Bioorganic & medicinal chemistry letters.

[27]  K. Peter,et al.  Amyloid Plaques Dissociate Pentameric to Monomeric C‐Reactive Protein: A Novel Pathomechanism Driving Cortical Inflammation in Alzheimer's Disease? , 2012, Brain pathology.

[28]  Y. Hu,et al.  Amides of xanthurenic acid as zinc-dependent inhibitors of Lp-PLA(2). , 2012, Bioorganic & medicinal chemistry letters.

[29]  E. Dennis,et al.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. , 2011, Chemical reviews.

[30]  L. Baltzer.  Crossing borders to bind proteins—a new concept in protein recognition based on the conjugation of small organic molecules or short peptides to polypeptides from a designed set , 2011, Analytical and bioanalytical chemistry.

[31]  K. Caldwell,et al.  Powerful protein binders from designed polypeptides and small organic molecules--a general concept for protein recognition. , 2011, Angewandte Chemie.

[32]  D. Reinhardt,et al.  1-(5-Carboxyindol-1-yl)propan-2-one inhibitors of human cytosolic phospholipase A2α: effect of substituents in position 3 of the indole scaffold on inhibitory potency, metabolic stability, solubility, and bioavailability. , 2010, Journal of medicinal chemistry.

[33]  L. Badimón,et al.  Modified C‐Reactive Protein Is Expressed by Stroke Neovessels and Is a Potent Activator of Angiogenesis In Vitro , 2010, Brain pathology.

[34]  H. Bannasch,et al.  C-reactive protein: How conformational changes influence inflammatory properties , 2009, Cell cycle.

[35]  A. Murphy,et al.  Dissociation of Pentameric to Monomeric C-Reactive Protein on Activated Platelets Localizes Inflammation to Atherosclerotic Plaques , 2009, Circulation research.

[36]  J. Filep,et al.  Monomeric C‐reactive protein activates endothelial cells via interaction with lipid raft microdomains , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  J. D. Clark,et al.  Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib. , 2008, Journal of medicinal chemistry.

[38]  J. D. Clark,et al.  Benzenesulfonamide indole inhibitors of cytosolic phospholipase A2alpha: optimization of in vitro potency and rat pharmacokinetics for oral efficacy. , 2008, Bioorganic & medicinal chemistry.

[39]  V. Hruby,et al.  Development of Novel Enkephalin Analogues that Have Enhanced Opioid Activities at Both μ and δ Opioid Receptors , 2007 .

[40]  M. Nobuyoshi,et al.  The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis Published, JLR Papers in Press, January 29, 2007. , 2007, Journal of Lipid Research.

[41]  R. Kraft,et al.  N-(p-amylcinnamoyl)anthranilic acid (ACA): a phospholipase A(2) inhibitor and TRP channel blocker. , 2007, Cardiovascular drug reviews.

[42]  S. Khor,et al.  Discovery of Ecopladib, an Indole Inhibitor of Cytosolic Phospholipase Α2α , 2007 .

[43]  Takao Shimizu,et al.  Biochemical properties and pathophysiological roles of cytosolic phospholipase A2s. , 2006, Biochimica et biophysica acta.

[44]  W. Lee,et al.  Potent inhibitors of lipoprotein-associated phospholipase A(2): benzaldehyde O-heterocycle-4-carbonyloxime. , 2006, Bioorganic & medicinal chemistry letters.

[45]  Steven V. Ley,et al.  Targeting C-reactive protein for the treatment of cardiovascular disease , 2006, Nature.

[46]  M. Gelb,et al.  The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding. , 2006, Journal of medicinal chemistry.

[47]  A. Zalewski,et al.  Role of Lipoprotein-Associated Phospholipase A2 in Atherosclerosis: Biology, Epidemiology, and Possible Therapeutic Target , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[48]  W. Lee,et al.  (E)-Phenyl- and -heteroaryl-substituted O-benzoyl-(or acyl)oximes as lipoprotein-associated phospholipase A2 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[49]  Irving Kushner,et al.  C-reactive Protein* , 2004, Journal of Biological Chemistry.

[50]  J. Filep,et al.  Conformational Rearrangement in C-Reactive Protein Is Required for Proinflammatory Actions on Human Endothelial Cells , 2004, Circulation.

[51]  James G. Bollinger,et al.  Inhibition of the complete set of mammalian secreted phospholipases A(2) by indole analogues: a structure-guided study. , 2004, Bioorganic & medicinal chemistry.

[52]  Christine Gaboriaud,et al.  The Crystal Structure of the Globular Head of Complement Protein C1q Provides a Basis for Its Versatile Recognition Properties* , 2003, Journal of Biological Chemistry.

[53]  Hung‐Yuan Cheng,et al.  The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2. , 2003, Bioorganic & medicinal chemistry letters.

[54]  Hung‐Yuan Cheng,et al.  The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man. , 2002, Bioorganic & medicinal chemistry letters.

[55]  J. Borensztajn,et al.  Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions. , 2002, The Biochemical journal.

[56]  E. Dennis,et al.  Novel 2-oxoamide inhibitors of human group IVA phospholipase A(2). , 2002, Journal of medicinal chemistry.

[57]  Katsutoshi Yamada,et al.  Characterization of a novel inhibitor of cytosolic phospholipase A2alpha, pyrrophenone. , 2002, The Biochemical journal.

[58]  D. Murray,et al.  Design and synthesis of a novel and potent series of inhibitors of cytosolic phospholipase A(2) based on a 1,3-disubstituted propan-2-one skeleton. , 2002, Journal of medicinal chemistry.

[59]  H. Boyd,et al.  Potent, orally active inhibitors of lipoprotein-associated phospholipase A(2): 1-(biphenylmethylamidoalkyl)-pyrimidones. , 2002, Bioorganic & medicinal chemistry letters.

[60]  J. Volanakis,et al.  Topology and Structure of the C1q-Binding Site on C-Reactive Protein1 , 2001, The Journal of Immunology.

[61]  Katsutoshi Yamada,et al.  Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2: synthesis of potent and crystallized 4-triphenylmethylthio derivative 'pyrrophenone'. , 2001, Bioorganic & medicinal chemistry letters.

[62]  G. Lowe,et al.  Lipoprotein-Associated Phospholipase A2as an Independent Predictor of Coronary Heart Disease , 2000 .

[63]  D. Tew,et al.  2-(Alkylthio)pyrimidin-4-ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A2. , 2000, Bioorganic & medicinal chemistry letters.

[64]  S. Wood,et al.  The physiological structure of human C-reactive protein and its complex with phosphocholine. , 1999, Structure.

[65]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[66]  D. Tew,et al.  Mechanism of inhibition of LDL phospholipase A2 by monocyclic-beta-lactams. Burst kinetics and the effect of stereochemistry. , 1998, Biochemistry.

[67]  D. R. Berry,et al.  Indole inhibitors of human nonpancreatic secretory phospholipase A2. 2. Indole-3-acetamides with additional functionality. , 1996, Journal of medicinal chemistry.

[68]  D. R. Berry,et al.  Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides. , 1996, Journal of medicinal chemistry.

[69]  Katsutoshi Yamada,et al.  Potent inhibitors of secretory phospholipase A2: synthesis and inhibitory activities of indolizine and indene derivatives. , 1996, Journal of medicinal chemistry.

[70]  J.-P. Wery,et al.  Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2 , 1995, Nature Structural Biology.

[71]  N. Gensmantel,et al.  Discovery of new non-phospholipid inhibitors of the secretory phospholipases A2. , 1994, Journal of medicinal chemistry.

[72]  M. Gelb,et al.  Slow- and tight-binding inhibitors of the 85-kDa human phospholipase A2. , 1993, Biochemistry.

[73]  E. Dennis,et al.  Defining the dimensions of the catalytic site of phospholipase A2 using amide substrate analogs , 1992 .

[74]  J. Brownell,et al.  Fatty acid amides: scooting mode-based discovery of tight-binding competitive inhibitors of secreted phospholipases A2. , 1992, Journal of medicinal chemistry.

[75]  W U Primrose,et al.  Design and synthesis of some substrate analogue inhibitors of phospholipase A2 and investigations by NMR and molecular modeling into the binding interactions in the enzyme-inhibitor complex. , 1992, Journal of medicinal chemistry.

[76]  D. Clawson,et al.  Structure of recombinant human rheumatoid arthritic synovial fluid phospholipase A2 at 2.2 Å resolution , 1991, Nature.

[77]  M. Gelb,et al.  Phosphonate-containing phospholipid analogues as tight-binding inhibitors of phospholipase-A2 , 1988 .

[78]  E. Dennis,et al.  1-Stearyl,2-stearoylaminodeoxy phosphatidylcholine, a potent reversible inhibitor of phospholipase A2. , 1986, Biochemical and biophysical research communications.

[79]  S. C. S. and.  N-1 Substituted Pyrimidin-4-ones: Novel, Orally Active Inhibitors of Lipoprotein-Associated Phospholipase A2. , 2010 .

[80]  D. R. Berry,et al.  Indole inhibitors of human nonpancreatic secretory phospholipase A2. 1. Indole-3-acetamides. , 1996, Journal of medicinal chemistry.

[81]  M. Pepys,et al.  Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. , 1983, Advances in immunology.

[82]  Robert V Farese,et al.  Atvb in Focus Novel Approaches to the Treatment of Dyslipidemia Inhibition of Triglyceride Synthesis as a Treatment Strategy for Obesity Lessons from Dgat1-deficient Mice Dgat Enzymes and Triglyceride Synthesis , 2022 .